Corrigendum: Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling study

Frontiers in Immunology

Immunology

Jason V. Baker¹  Calvin Cohen²  Kathleen Melbourne²  Connie Kim²  Laura Lara³  Jose Luis Gonzalez³  Sergio Serrano-Villar⁴  Santiago Moreno⁵  Maria João Janeiro⁶  Filipa Aragão⁷ 

[1] Division of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, MN, United States;Department of Medicine, University of Minnesota, Minneapolis, MN, United States;HIV Medical Affairs, Gilead Sciences Inc., Foster City, CA, United States;HIV Medical Affairs, Gilead Sciences Inc., Madrid, Spain;Hospital Universitario Ramón y Cajal, Infectious Diseases, Instituto de Investigación Sanitaria Ramón y Cajal (IRYCIS), Madrid, Spain;CIBERInfec, Instituto de Salud Carlos III, Madrid, Spain;Hospital Universitario Ramón y Cajal, Infectious Diseases, Instituto de Investigación Sanitaria Ramón y Cajal (IRYCIS), Madrid, Spain;CIBERInfec, Instituto de Salud Carlos III, Madrid, Spain;Department of Medicine, Alcalá University, Madrid, Spain;Maple Health Group, New York, NY, United States;Maple Health Group, New York, NY, United States;Incremental Action Consulting Lda, Lisbon, Portugal;NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal;

关键词: antiretroviral;    HIV;    inflammation;    interleukin-6;    Markov;    three-drug regimen;    two-drug regimen;   

DOI  :  10.3389/fimmu.2023.1148980

 received in 2023-01-20, accepted in 2023-02-07,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Serrano-Villar, Cohen, Baker, Janeiro, Aragão, Melbourne, Gonzalez, Lara, Kim and Moreno